mRNA vaccine development for cholangiocarcinoma:a precise pipeline  

作　　者：Tian-Yu Tang Xing Huang Gang Zhang Ming-Hao Lu Ting-Bo Liang 

机构地区：[1]Department of Hepatobiliary and Pancreatic Surgery,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China [2]Zhejiang Provincial Key Laboratory of Pancreatic Disease,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China [3]Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases,Hangzhou 310003,China [4]Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province,Hangzhou 310009,China [5]Cancer Center,Zhejiang University,Hangzhou 310058,China

出　　处：《Military Medical Research》2023年第2期262-267,共6页军事医学研究（英文版）

基　　金：supported by the National Natural Science Foundation of China(31970696,81502975,81830089,U20A20378,82188102);the Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholar(LR22H160010);the National Key Research and Development Program(2019YFC1316000);the Zhejiang Provincial Key Research and Development Program(2019C03019);the Zhejiang Provincial College Student Science and Technology Innovation Activity Plan-College Student Innovation and Entrepreneurship Incubation Program(Young Talent Program)(2022R40122)。

摘　　要：Cholangiocarcinoma(CHOL)is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments,including immune checkpoint blockade therapy.The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases,however,its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection.A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines.In spite of a promising prospect,further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.

关 键 词：Cholangiocarcinoma(CHOL) mRNA vaccine Tumor antigen Immune subtype Immune microenvironment 

分 类 号：R735.8[医药卫生—肿瘤]